Τίτλος:
Carboplatin alone compared with its combination with epirubicin and
cyclophosphamide in untreated advanced epithelial ovarian cancer: A
Hellenic Co-operative Oncology Group study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
We compared, in a multicentric randomised prospective study, the
efficacy and toxicity of carboplatin 400 mg/m(2) as a single agent (CB)
to a combination of carboplatin 300 mg/m(2), epirubicin 50 mg/m(2) and
cyclophosphamide 500 mg/m(2) (CB-EC) in advanced ovarian cancer
patients. The treatment was scheduled to be administered every 3 weeks
for six courses. Following initial laparotomy and cytoreductive surgery,
130 previously untreated patients entered the study. 73 patients were
treated with carboplatin alone white 57 received the combination
chemotherapy. In the majority of the patients, the regimens had to be
given every 4 weeks due to myelosuppression. Nausea, vomiting and
alopecia were more severe in the CB-EC arm. Overall, clinical complete
response was observed in 73 (56%) and partial response in 20 (15%)
patients. The median time to progression was 16.89 months and median
survival was 29.54 months. No significant differences in response rate,
time to progression, disease-free survival and overall survival were
observed between the two treatment arms. The prognostic role of residual
disease after initial surgery, complete remission at second-look
laparotomy, tumour stage and performance status was confirmed.
Συγγραφείς:
Skarlos, DV
Aravantinos, G
Kosmidis, P
Pavlidis, N and
Gennatas, K
Beer, M
Mylonakis, N
Makrantonakis, P and
Klouvas, G
Karpathios, S
Linardou, H
Konstantaras, C and
Fountzilas, G
Περιοδικό:
EUROPEAN JOURNAL OF CANCER
Εκδότης:
Elsevier Sci Ltd, Exeter, United Kingdom
Λέξεις-κλειδιά:
ovarian cancer; carboplatin-based chemotherapy
DOI:
10.1016/0959-8049(95)00537-4
